The imiquimod mouse model is the most widely-used psoriasiform model for studying psoriatic skin disease due to the capability of TLR7 agonist imiquimod to activate plasmacytoid dendritic cells (pDCs), which are also implicated in mediating early events in human psoriasis pathogenesis (85, 86), Card14−/− mice did not display thickening of the epidermis or immune cell infiltration of IL-17- and IL-22-secreting γδ T cells, characteristic of the imiquimod model. Here, CARD14 is linked to psoriasis.